These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 25770357

  • 1. A semi-automated mass spectrometric immunoassay coupled to selected reaction monitoring (MSIA-SRM) reveals novel relationships between circulating PCSK9 and metabolic phenotypes in patient cohorts.
    Gauthier MS, Pérusse JR, Awan Z, Bouchard A, Tessier S, Champagne J, Krastins B, Byram G, Chabot K, Garneau P, Rabasa-Lhoret R, Faubert D, Lopez MF, Seidah NG, Coulombe B.
    Methods; 2015 Jun 15; 81():66-73. PubMed ID: 25770357
    [Abstract] [Full Text] [Related]

  • 2. Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics.
    Gauthier MS, Awan Z, Bouchard A, Champagne J, Tessier S, Faubert D, Chabot K, Garneau PY, Rabasa-Lhoret R, Seidah NG, Ridker PM, Genest J, Coulombe B.
    J Clin Lipidol; 2018 Jun 15; 12(4):1027-1038. PubMed ID: 29699916
    [Abstract] [Full Text] [Related]

  • 3. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P, Stenman UH, Gylling H.
    Clin Sci (Lond); 2015 Sep 15; 129(5):439-46. PubMed ID: 25857271
    [Abstract] [Full Text] [Related]

  • 4. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M, Ishihara M, Yuasa Y, Makino H, Yanagi K, Tamanaha T, Kishimoto I, Kujiraoka T, Hattori H, Harada-Shiba M.
    J Clin Endocrinol Metab; 2015 Jan 15; 100(1):E41-9. PubMed ID: 25313916
    [Abstract] [Full Text] [Related]

  • 5. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
    Alghamdi RH, O'Reilly P, Lu C, Gomes J, Lagace TA, Basak A.
    Eur J Med Chem; 2015 Mar 06; 92():890-907. PubMed ID: 25679794
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
    Guardiola M, Plana N, Ibarretxe D, Cabré A, González M, Ribalta J, Masana L.
    Clin Sci (Lond); 2015 Jun 06; 128(12):877-82. PubMed ID: 25649668
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
    Brouwers MC, Konrad RJ, van Himbergen TM, Isaacs A, Otokozawa S, Troutt JS, Schaefer EJ, van Greevenbroek MM, Stalenhoef AF, de Graaf J.
    Nutr Metab Cardiovasc Dis; 2013 Nov 06; 23(11):1115-21. PubMed ID: 23333725
    [Abstract] [Full Text] [Related]

  • 10. The apoB-to-PCSK9 ratio: A new index for metabolic risk in humans.
    Wassef H, Bissonnette S, Saint-Pierre N, Lamantia V, Cyr Y, Chrétien M, Faraj M.
    J Clin Lipidol; 2015 Nov 06; 9(5):664-75. PubMed ID: 26350813
    [Abstract] [Full Text] [Related]

  • 11. PCSK9: a key modulator of cardiovascular health.
    Seidah NG, Awan Z, Chrétien M, Mbikay M.
    Circ Res; 2014 Mar 14; 114(6):1022-36. PubMed ID: 24625727
    [Abstract] [Full Text] [Related]

  • 12. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.
    Lipari MT, Li W, Moran P, Kong-Beltran M, Sai T, Lai J, Lin SJ, Kolumam G, Zavala-Solorio J, Izrael-Tomasevic A, Arnott D, Wang J, Peterson AS, Kirchhofer D.
    J Biol Chem; 2012 Dec 21; 287(52):43482-91. PubMed ID: 23135270
    [Abstract] [Full Text] [Related]

  • 13. Effect of Leptin Replacement on PCSK9 in ob/ob Mice and Female Lipodystrophic Patients.
    Levenson AE, Haas ME, Miao J, Brown RJ, de Ferranti SD, Muniyappa R, Biddinger SB.
    Endocrinology; 2016 Apr 21; 157(4):1421-9. PubMed ID: 26824363
    [Abstract] [Full Text] [Related]

  • 14. Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects.
    Kwakernaak AJ, Lambert G, Dullaart RP.
    Clin Biochem; 2012 Nov 21; 45(16-17):1522-4. PubMed ID: 22809551
    [Abstract] [Full Text] [Related]

  • 15. PCSK9 levels in abdominally obese men: association with cardiometabolic risk profile and effects of a one-year lifestyle modification program.
    Arsenault BJ, Pelletier-Beaumont E, Alméras N, Tremblay A, Poirier P, Bergeron J, Després JP.
    Atherosclerosis; 2014 Oct 21; 236(2):321-6. PubMed ID: 25128757
    [Abstract] [Full Text] [Related]

  • 16. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
    Nekaies Y, Baudin B, Kelbousi S, Sakly M, Attia N.
    J Diabetes Complications; 2015 Oct 21; 29(8):1165-70. PubMed ID: 26412029
    [Abstract] [Full Text] [Related]

  • 17. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S, Xu RX, Guo YL, Zhang Y, Zhu CG, Sun J, Li JJ.
    Nutr Metab Cardiovasc Dis; 2015 Apr 21; 25(4):411-7. PubMed ID: 25466598
    [Abstract] [Full Text] [Related]

  • 18. Circulating PCSK9 levels correlate with the serum LDL cholesterol level in newborn infants.
    Araki S, Suga S, Miyake F, Ichikawa S, Kinjo T, Yamamoto Y, Kusuhara K.
    Early Hum Dev; 2014 Oct 21; 90(10):607-11. PubMed ID: 25134067
    [Abstract] [Full Text] [Related]

  • 19. Regulatory effects of peptides from the pro and catalytic domains of proprotein convertase subtilisin/kexin 9 (PCSK9) on low-density lipoprotein receptor (LDL-R).
    Palmer-Smith H, Basak A.
    Curr Med Chem; 2010 Oct 21; 17(20):2168-82. PubMed ID: 20423303
    [Abstract] [Full Text] [Related]

  • 20. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J, Bogsrud MP, Tveten K, Strøm TB, Holven K, Berge KE, Leren TP.
    Transl Res; 2012 Aug 21; 160(2):125-30. PubMed ID: 22683370
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.